TIDMEVG
RNS Number : 6722X
Evgen Pharma PLC
22 December 2023
Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Directorate Changes
-- Appointment of Toni Hänninen as Permanent CFO and Board Director
-- Retirement of Susan Clement-Davies as Board Member
Alderley Park, UK - 22 December 2023: Evgen Pharma plc (AIM:
EVG), a clinical stage drug development company developing
sulforaphane-based medicines, announces that Toni Hänninen has been
appointed as permanent Chief Financial Officer (CFO) and he will
join the Board of Directors as a Director. The Company also
announces that Non-Executive Director, Susan Clement-Davies, will
be retiring from the Board.
Toni Hänninen
Toni Hänninen was appointed interim CFO in September 2023. He is
now taking on the CFO role on a permanent basis and moving onto the
Board as a Director. His appointment is effective from 1 January
2024.
Toni was previously CFO at Faron Pharmaceuticals Ltd, an AIM and
Nasdaq First North listed clinical stage biopharmaceutical company
based in the Finland and the US, developing novel treatments for
medical conditions with significant unmet needs. He holds over 20
years of experience in business development and senior finance
roles in both public and private companies, working in mature and
emerging markets particularly in Europe and the USA where he has
accomplished successful fundraises, transactions and fiscal
management in the sector. Toni has an MBA from the Helsinki School
of Economics (now Aalto University).
Retiring board member
Evgen Pharma also confirms that Susan Clement-Davies is retiring
from her position as Non-Executive Director on the 31 December 2023
in order to focus on her other board positions. Susan has been on
the Evgen Pharma board since 2018 and has provided valuable insight
and expertise in that time.
Dr Susan Foden, Non-Executive Chair of Evgen Pharma said:
"I am very pleased to welcome Toni in as permanent CFO and I
look forward to working with him on the board. Toni's broad company
experience is already making a difference to Evgen and he is
providing considerable support to the rest of the executive team in
driving projects forward.
"On behalf of the Board, I also want to thank Susan for her
significant contributions to the Board and the company for the past
five years and wish her well for the future."
Toni Hänninen, CFO of Evgen said:
"I'm delighted to join the Evgen executive team and Board as
permanent CFO and Executive Director. I've thoroughly enjoyed
working with Huw, Helen and the rest of the team so far, and look
forward to helping build value for shareholders."
Huw Jones, CEO of Evgen said:
"Toni's considerable skill set is highly complementary to the
rest of our talented team and it's great to be working with him.
Welcome to the team on a permanent basis Toni.
As we reported in the half year results in October, we have made
substantial progress against strategic goals, despite the toughness
of the market environment. We continue to be well positioned to
commercialise the potential of SFX-01 both through our own studies
and through a range of collaborations. We are looking forward to a
busy 2024."
-Ends-
Enquiries:
Evgen Pharma plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO +44 1625 466591
Cavendish (Nominated Advisor
and Broker)
Geoff Nash / Teddy Whiley (Corporate
Finance)
Nigel Birks (ECM) +44 20 7220 0500
Instinctif Partners +44 207 457 2020
Melanie Toyne-Sewell / Jack Kincade evgen@instinctif.com
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the highly biologically
active compound sulforaphane and novel proprietary analogues based
on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer and recently a Phase 1b study of the Company's new enteric
coated tablet formulation. The FDA has granted Orphan Drug status
to SFX-01 in malignant glioma. SFX-01 will be investigated
initially in this indication as an investigator sponsored study in
the Netherlands supported by a substantial non-dilutive grant.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and the US as part of
the continuing strategy to build the scientific data for the
compound. Recently, Evgen completed an out-licensing transaction
with Stalicla SA, a Swiss specialist company in neurodevelopmental
disorders, commencing with autism spectrum disorder. The deal, if
successful, will generate milestone payments of $160.5m and a
double-digit royalty on sales.
The Company has its headquarters and registered office at
Alderley Park, Cheshire. It is listed on AIM in London and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com .
INFORMATION REQUIRED UNDER RULE 17 AND SCHEDULE 2, PARAGRAPH (G)
OF THE AIM RULES FOR COMPANIES ("AIM RULES")
Full name: Toni Markus Antero Hanninen
Age: 46
Current directorships or partnerships: Historic directorships and
partnerships in previous 5
years
Borealito GmbH
There is no further information to be disclosed in relation to
the appointment pursuant to Rule 17 and Schedule 2, paragraph (g)
of the AIM Rules.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEFLFLXLLBFBK
(END) Dow Jones Newswires
December 22, 2023 02:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De May 2023 a May 2024
